Related Experiment Videos
[Intoxications by hallucinogenic mushrooms]
M Pierrot1, P Josse, M F Raspiller
1Centre Anti-Poison, Centre d'Evaluation et d'Information sur la Pharmacodépendance, CHU, 29, avenue Maréchal-de-Lattre-de-Tassigny, CO n degrees 34, 54035 Nancy Cedex.
Annales De Medecine Interne
|December 6, 2000
Summary
Consumption of Psilocybe semilanceata mushrooms has increased in France over 15 years. This review covers clinical cases, epidemiology, and pharmacology of these hallucinogenic intoxications.
Area of Science:
- Mycology
- Toxicology
- Psychopharmacology
Background:
- Psilocybe semilanceata mushrooms contain psilocybin and psilocin, potent psychoactive compounds.
- These tryptamine derivatives are known for their stimulating, psychedelic, and hallucinogenic effects.
Observation:
- A notable increase in Psilocybe semilanceata consumption has been observed in France over the past 15 years.
- This trend is linked to youth cultural and entertainment movements.
- Clinical cases present diagnostic challenges in emergency settings.
Findings:
- Psilocybin and psilocin are the primary active compounds responsible for the observed hallucinogenic effects.
- Intoxications can lead to severe and potentially fatal complications.
Implications:
- Understanding the epidemiology and clinical presentation of Psilocybe semilanceata intoxication is crucial for emergency medical services.
- Further research into the long-term effects and management of these intoxications is warranted.